Last reviewed · How we verify

NCT03074500

Kinesiotaping in Lateral Epicondylitis

Completed NA Results posted Last updated 3 October 2019
What this trial tests

NA trial testing Kinesiotaping in Lateral Epicondylitis in 30 participants. Completed in 30 April 2018.

Timeline
10 March 2017
Primary endpoint
1 April 2018
30 April 2018

Quick facts

Lead sponsorMarmara University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment30
Start date10 March 2017
Primary completion1 April 2018
Estimated completion30 April 2018
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Marmara University

Who can join

Adults 18 to 60, any sex, with Lateral Epicondylitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Patient Rated Tennis Elbow Evaluation (PRTEE) Primary · 0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)

PRTEE is a 15-item questionnaire designed to measure the forearm pain and disability in patients with LE. PRTEE allows patients to rate their levels of elbow pain and disability from 0 to 10. Test consists of 2 subscales: 1) Pain subscale \[5 items\] (0 = no pain, 10 = worst imaginable) 2) Function subscale \[Specific activities - 6 items, Usual activities - 4 items\] (0 = no difficulty, 10 = unable to do). A total score can be computed on a scale of 100 (0 = no disability).

Baseline
GroupValue95% CI
Kinesiotaping4943.88 – 73
Sham Taping53.7548.62 – 63
Control49.2541 – 57.5
After Treatment
GroupValue95% CI
Kinesiotaping26.516.87 – 39.75
Sham Taping50.2542 – 58.37
Control46.2537.5 – 54.12
4 weeks After Treatment
GroupValue95% CI
Kinesiotaping29.2516.37 – 29.25
Sham Taping47.541.37 – 61.37
Control44.538.87 – 53.62
The Disabilities of the Arm, Shoulder and Hand Score (QuickDash) Secondary · 0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)

The patients will be requested to score from 1 to 5 points any difficulty experienced during different daily activities related to the upper extremity. Test has 1 module of compulsory items and two optional modules: work module (4 items) and sport/performing arts module (4 items). Scores range from 0 to 100, where higher scores indicate more disability.

Baseline
GroupValue95% CI
Kinesiotaping5041.5 – 74.43
Sham Taping46.5738.6 – 62.49
Control46.5933.81 – 57.39
After Treatment
GroupValue95% CI
Kinesiotaping29.510.4 – 59.7
Sham Taping47.7238.04 – 53.97
Control39.7733.52 – 49.42
4 weeks After Treatmentt
GroupValue95% CI
Kinesiotaping18.184.55 – 34.1
Sham Taping47.7234.62 – 56.81
Control39.7531.81 – 46.59
Visual Analogue Scale (VAS) at Rest Secondary · 0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)

Pain on lateral epicondyle at rest during the day was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.

Baseline
GroupValue95% CI
Kinesiotaping1.50 – 3.25
Sham Taping1.50 – 3.25
Control30 – 4
Immediate Effect
GroupValue95% CI
Kinesiotaping00 – 0.5
Sham Taping1.50 – 3.25
ControlNANA – NA
After Treatment
GroupValue95% CI
Kinesiotaping00 – 0.25
Sham Taping0.50 – 3
Control10 – 3.5
4 weeks After Treatment
GroupValue95% CI
Kinesiotaping00 – 0
Sham Taping10 – 3.25
Control1.50.75 – 3
Visual Analogue Scale (VAS) at Daily Activity Secondary · 0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)

Pain on lateral epicondyle during daily activity was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.

Baseline
GroupValue95% CI
Kinesiotaping6.55 – 7.25
Sham Taping7.56.75 – 8
Control75 – 7
Immediate Effect
GroupValue95% CI
Kinesiotaping51.5 – 6.25
Sham Taping76 – 8
ControlNANA – NA
After Treatment
GroupValue95% CI
Kinesiotaping32 – 5
Sham Taping75.75 – 8
Control55 – 7
4 weeks After Treatment
GroupValue95% CI
Kinesiotaping31.75 – 5.25
Sham Taping6.54.75 – 7.25
Control5.55 – 7
Visual Analogue Scale (VAS) at Night Secondary · 0. week (Baseline), 2. week (After Treatment), 6. week (4 weeks After Treatment)

Pain on lateral epicondyle at night was evaluated with the visual analog scale (VAS 0-10 cm). Higher score indicates more pain.

Before Treatment
GroupValue95% CI
Kinesiotaping2.50 – 4.5
Sham Taping2.50 – 3.5
Control3.50 – 5.75
After Treatment
GroupValue95% CI
Kinesiotaping00 – 0.25
Sham Taping20 – 3.5
Control10 – 3.25
4 weeks After Treatment
GroupValue95% CI
Kinesiotaping00 – 0
Sham Taping20 – 3.25
Control00 – 3.25
Painless Grip Strength Secondary · 0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)

Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip the dynamometer until (s)he feel pain in elbow. Three evaluations will be made with resting periods in between and average scores will be recorded.

Baseline
GroupValue95% CI
Kinesiotaping148 – 19.75
Sham Taping122 – 25
Control139.5 – 20.5
Immediate Effect
GroupValue95% CI
Kinesiotaping1710 – 23
Sham Taping133.75 – 27.75
ControlNANA – NA
After Treatment
GroupValue95% CI
Kinesiotaping17.514.75 – 28.25
Sham Taping1310 – 21.25
Control159.5 – 20.5
4 weeks After Treatment
GroupValue95% CI
Kinesiotaping2017 – 28.75
Sham Taping14.510 – 24.5
Control14.59.5 – 20.5
Grip Strength Secondary · 0. week (Baseline), Immediate Effect (right after first taping in KT and sham taping groups), 2. week (After Treatment) and 6. week (4 weeks After Treatment)

Grip strength will be measured using a hand held dynamometer (JAMAR, Sammons Preston, Inc., Bolingbrook, IL). Patients will be asked to grip with maximum strength. Three evaluations will be made with resting periods in between and average scores will be recorded.

Baseline
GroupValue95% CI
Kinesiotaping2014.75 – 27.5
Sham Taping19.514.75 – 30.25
Control23.515 – 28.25
Immediate Effect
GroupValue95% CI
Kinesiotaping2216.5 – 29.25
Sham Taping19.514.5 – 32.5
ControlNANA – NA
After Treatment
GroupValue95% CI
Kinesiotaping22.517.5 – 29.25
Sham Taping2014.5 – 27.25
Control2419 – 25.75
4 weeks After Treatment
GroupValue95% CI
Kinesiotaping2521.5 – 28.75
Sham Taping2112 – 28
Control2418.5 – 27

Adverse events — posted to ClinicalTrials.gov

Time frame: 6 weeks. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Kinesiotaping
Serious: 0/11 (0%)
Deaths: 0/11
Sham Taping
Serious: 0/11 (0%)
Deaths: 0/11
Control
Serious: 0/11 (0%)
Deaths: 0/11
Other adverse events (1 terms — click to expand)

ReactionSystemKinesiotapingSham TapingControl
Allergy to TapeSkin and subcutaneous tissue disorders

Data from ClinicalTrials.gov NCT03074500 adverse events section.

Sponsor's own description

The aim of this study is to compare the effects of kinesiology taping with exercise, sham taping with exercise and exercise alone for lateral epicondylitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Manual therapy and exercise for lateral elbow pain.
    Wallis JA, Bourne AM, Jessup RL, Johnston RV, et al · · 2024 · cited 7× · PMID 38802121 · DOI 10.1002/14651858.cd013042.pub2

Verify or expand the search:

Other trials of Kinesiotaping

Trials testing the same drug.

Other recruiting trials for Lateral Epicondylitis

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03074500.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing